Table 2.

Overall response rate and early tumor shrinkage 6 weeks after treatment

	All (n = 103)	GEMOX (n = 54)	GEMOX plus erlotinib (n = 49)	p-value
Early tumor shrinkage at 6 weeks
10 %≤	53 (51.4 %)	22 40.7 %)	31 (63.2 %)	0.03
Response at 6 weeks (RECIST)	18 (17.4 %)	3 (5.6 %)	15 (30.6 %)	0.00
Complete response	0 (0.0 %)	0 (0.0 %)	0 (0.0 %)
Partial response	18 (17.4 %)	3 (5.6 %)	15 (30.6 %)
Stable disease	72 (69.9 %)	44 (81.5 %)	28 (57.1)
Progressive disease	13 (12.6 %)	7 (13.0 %)	6 (12.2 %)
Overall response (RECIST)	30 (29.0 %)	10 (18.6 %)	20 (40.8 %)	0.02
Complete response	1 (0.9 %)	1 (1.9 %)	0 (0.0 %)
Partial response	29 (28.1 %)	9 (16.7 %)	20 (40.8 %)
Stable disease	50 (48.5 %)	32 (59.3 %)	18 (36.7 %)
Progressive disease	23 (22.3 %)	12 (22.2 %)	11 (22.4 %)